Evicenter
P&T meetings

Lytenava

Neovascular age-related macular degeneration

Also known as bevacizumab-vikg
Regulatory submission
BLA approved July 2026
50 sources

Section 6 of 6

References

50 sources

  1. Almony et al. (2021) (opens in a new tab)
  2. American Academy of Ophthalmology (opens in a new tab)
  3. Armendariz et al. (2024) (opens in a new tab)
  4. BrightFocus Foundation (opens in a new tab)
  5. CATT Research Group (2011) (opens in a new tab)
  6. ClinicalTrials.gov NCT03834753 (opens in a new tab)
  7. ClinicalTrials.gov NCT03844074 (opens in a new tab)
  8. ClinicalTrials.gov NCT04516278 (opens in a new tab)
  9. ClinicalTrials.gov NCT05112861 (opens in a new tab)
  10. ClinicalTrials.gov NCT06190093 (opens in a new tab)
  11. Edison et al. (2015) (opens in a new tab)
  12. Estreicher et al. (2026) (opens in a new tab)
  13. Eyewire+ (2026) (opens in a new tab)
  14. FDA (2026) (opens in a new tab)
  15. Genentech LUCENTIS prescribing information (2024) (opens in a new tab)
  16. Genentech VABYSMO prescribing information (2026) (opens in a new tab)
  17. Giustolisi et al. (2011) (opens in a new tab)
  18. Huang et al. (2024) (opens in a new tab)
  19. Korva-Gurung et al. (2023) (opens in a new tab)
  20. Kozhevnikova et al. (2022) (opens in a new tab)
  21. Kuzmina and Yakovlev (2025) (opens in a new tab)
  22. Li and Fekrat (2023) (opens in a new tab)
  23. Lombardo et al. (2025) (opens in a new tab)
  24. Lucenteforte et al. (2026) (opens in a new tab)
  25. National Eye Institute (opens in a new tab)
  26. National Eye Institute (opens in a new tab)
  27. Outlook Therapeutics (2026) (opens in a new tab)
  28. Outlook Therapeutics FDA acceptance announcement (2026) (opens in a new tab)
  29. Outlook Therapeutics FDA approval announcement (2026) (opens in a new tab)
  30. Outlook Therapeutics Form 10-Q (2026) (opens in a new tab)
  31. Outlook Therapeutics Form 8-K (2026) (opens in a new tab)
  32. Outlook Therapeutics NORSE EIGHT complete twelve-week results press release (2025) (opens in a new tab)
  33. Outlook Therapeutics NORSE EIGHT preliminary topline results press release (2024) (opens in a new tab)
  34. Outlook Therapeutics NORSE EIGHT presentation press release (2025) (opens in a new tab)
  35. Outlook Therapeutics NORSE ONE topline results press release (2020) (opens in a new tab)
  36. Outlook Therapeutics NORSE THREE safety results press release (2021) (opens in a new tab)
  37. Outlook Therapeutics NORSE TWO 12-month safety results press release (2021) (opens in a new tab)
  38. Outlook Therapeutics regulatory update (2023) (opens in a new tab)
  39. Outlook Therapeutics third quarter fiscal year 2026 results (2026) (opens in a new tab)
  40. Outlook Therapeutics, Inc. (2026) (opens in a new tab)
  41. Pugazhendhi et al. (2021) (opens in a new tab)
  42. Rahhal et al. (2025) (opens in a new tab)
  43. Regeneron EYLEA prescribing information (2024) (opens in a new tab)
  44. Reitan et al. (2023) (opens in a new tab)
  45. Review of Ophthalmology (2022) (opens in a new tab)
  46. Sambhara et al. (2026) (opens in a new tab)
  47. Singh et al. (2025) (opens in a new tab)
  48. Somasundaran et al. (2020) (opens in a new tab)
  49. Tran et al. (2023) (opens in a new tab)
  50. White et al. (2022) (opens in a new tab)